Anastrozole

Third-generation non-steroidal aromatase inhibitor — FDA-approved 1995 for postmenopausal HR+ breast cancer, off-label workhorse for TRT-induced and AAS-induced high-E2 management in men (~0.25-1 mg pulsed, twice weekly) and for adolescent idiopathic gynecomastia / precocious puberty in pediatric trials. For Dylan at 20, eugonadal, no anabolics, no TRT, no documented high E2: NOT-RELEVANT, HIGH confidence. The crucial Dylan-specific point: crashing E2 in a young man with an intact HPG axis is actively harmful — joint pain, libido loss, lipid disruption, mood crash, accelerated bone density loss. AI use without elevated baseline E2 is iatrogenic injury. Bloodwork flag: June 2026 sensitive E2 panel — if E2 >50 pg/mL symptomatically, this file moves to WATCH-LIST and we revisit. Otherwise file stays archival, documented because users searching "estrogen control" or "AI" reach this entry.

Anastrozole is a non-steroidal, reversible, competitive inhibitor of aromatase (CYP19A1) — a cytochrome P450 enzyme expressed in adipose tissue, gonads, brain, bone, and breast tissue that catalyzes the rate-limiting step in estrogen biosynthesis: aromatic ring conversion of androgens to estrogens.

Substrates blocked:

• Testosterone → 17β-estradiol (E2)
• Androstenedione → estrone (E1)
• 16α-hydroxytestosterone → 16α-hydroxyestradiol

Class context:

• First-generation AIs: aminoglutethimide (1970s) — non-selective, blocks adrenal steroidogenesis broadly, obsolete
• Second-generation: formestane (steroidal), fadrozole — partial selectivity, mostly obsolete
• Third-generation (current standard):
  • Anastrozole (Arimidex): non-steroidal, reversible, ~80-85% aromatase suppression
  • Letrozole (Femara): non-steroidal, reversible, ~98% aromatase suppression (more potent, more crash-prone in male off-label use)
  • Exemestane (Aromasin): steroidal, irreversible (suicide inhibitor), ~85% suppression — different binding kinetics, often considered "smoother" by AAS users for that reason

Anastrozole occupies the heme-iron coordination site at aromatase's active center via reversible binding — half-life ~50 hours allows once-daily or pulsed twice-weekly dosing depending on indication. Selectivity is high: at therapeutic doses, no measurable inhibition of cortisol, aldosterone, or thyroid hormone synthesis (distinct from first-gen AIs).

Pharmacokinetics:

• Oral bioavailability: ~85% (well-absorbed)
• T-max: ~2 hours
• Plasma half-life: ~50 hours (long, supports pulsed dosing)
• Steady-state: ~7 days at 1 mg/day
• Protein binding: ~40% (low — wide tissue distribution)
• Metabolism: predominantly hepatic via N-dealkylation, hydroxylation, and glucuronidation. Minor CYP3A4 involvement (clinically not a major DDI driver).
• Excretion: primarily fecal as metabolites; ~10% renal as parent compound + metabolites
• Dose-response: linear PK 1-20 mg; aromatase suppression near-maximal at 1 mg/day in postmenopausal women — no benefit to higher doses for the FDA indication.

What anastrozole is NOT doing:

• Not blocking estrogen receptors (that's tamoxifen, raloxifene — SERMs, different class)
• Not lowering androgens (testosterone may actually rise mildly in men due to reduced negative feedback at the hypothalamus from lower E2)
• Not affecting cortisol/aldosterone (selective for aromatase only)
• Not directly affecting bone (effect on bone is indirect via reduced E2, which is the mediator of male bone density)

Indirect HPG effect in men: Lower E2 → less hypothalamic E2 negative feedback → modest ↑GnRH → ↑LH/FSH → ↑endogenous T. This is why anastrozole sometimes appears in fertility / hypogonadism off-label protocols as a "natural T booster" — but the magnitude is small, the mechanism is reversible, and the cost (low E2) usually outweighs the benefit.